Erste Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $374K | Hold |
40,000
| – | – | ﹤0.01% | 675 |
|
|
2025
Q1 | $314K | Hold |
40,000
| – | – | ﹤0.01% | 458 |
|
|
2024
Q4 | $308K | Hold |
40,000
| – | – | ﹤0.01% | 470 |
|
|
2024
Q3 | $305K | Hold |
40,000
| – | – | ﹤0.01% | 467 |
|
|
2024
Q2 | $244K | Hold |
40,000
| – | – | ﹤0.01% | 469 |
|
|
2024
Q1 | $206K | Hold |
40,000
| – | – | ﹤0.01% | 473 |
|
|
2023
Q4 | $244K | Hold |
40,000
| – | – | ﹤0.01% | 475 |
|
|
2023
Q3 | $290K | Hold |
40,000
| – | – | 0.01% | 454 |
|
|
2023
Q2 | $278K | Hold |
40,000
| – | – | ﹤0.01% | 464 |
|
|
2023
Q1 | $336K | Hold |
40,000
| – | – | 0.01% | 463 |
|
|
2022
Q4 | $447K | Hold |
40,000
| – | – | 0.01% | 434 |
|
|
2022
Q3 | $494K | Hold |
40,000
| – | – | 0.01% | 424 |
|
|
2022
Q2 | $432K | Hold |
40,000
| – | – | 0.01% | 446 |
|
|
2022
Q1 | $658K | Buy |
+40,000
| New | +$658K | 0.01% | 409 |
|